**All Interactions with Enfuvirtide (Fuzeon)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Enfuvirtide** | **Effect on Drug Levels** | **Effect on Enfuvirtide Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Rifampin[6](http://arv.ucsf.edu/insite?page=ar-00-02&param=11&post=4#6),  (Rifampicin)(Rifadin) | 600 mg QD on days 4-13 | 90 mg SQ BID on days 1-3 and 11-13 | No significant change | No significant change | - | - | No dose adjustment necessary |
| Ritonavir[6](http://arv.ucsf.edu/insite?page=ar-00-02&param=11&post=4#6),[7](http://arv.ucsf.edu/insite?page=ar-00-02&param=11&post=4#7)  (RTV)(Norvir) | 200 mg BID on days 4-7 | 90 mg SQ BID on days 1-7 | No significant change | Enfuvirtide Cmax: increased 24%; Cmin: no significant change; AUC: increased 22% | - | - | No dose adjustment necessary |
| Saquinavir[6](http://arv.ucsf.edu/insite?page=ar-00-02&param=11&post=4#6),[7](http://arv.ucsf.edu/insite?page=ar-00-02&param=11&post=4#7),[75](http://arv.ucsf.edu/insite?page=ar-00-02&param=11&post=4#75)  (SQV)(Fortovase, Invirase) | 1000 mg BID with ritonavir 100 mg BID on days 4-7 | 90 mg SQ BID on days 1-7 | No significant change | Enfuvirtide Cmax: no significant change; Cmin: increased 26%; AUC: no significant change | - | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 6: | Boyd M, Zhang X, Dorr A, et al. Lack of enzyme-inducing effecto of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 2003; 43: 1382-91. |
| 7: | Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-based saquinavir in HIV-1 infected patients. J Clin Pharmacol 2004; 44: 793-802. |
| 75: | Invirase [package insert]. Roche Laboratories Inc, Nutley, NJ, 2007. |